Effects of Dexmedetomidine on Oxygenation and Lung Mechanics in Morbidly Obese Patients Undergoing Bariatric Operations

Restrictive Lung Disease Clinical Trial

Official title:

Effects of Dexmedetomidine on Oxygenation and Lung Mechanics in Morbidly Obese Patients Undergoing Bariatric Operations: A Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02843698
• Other study ID #: N-12-2016
• Status: Completed
• Phase: Phase 4
• First received: July 20, 2016
• Last updated: August 25, 2017
• Start date: September 2016
• Est. completion date: August 26, 2017

Study information

• Verified date: August 2017
• Source: Cairo University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study aims to investigate the effect of dexmedetomidine on oxygenation and lung mechanics in morbidly obese patients

Description:

The patients of interest are morbid obese patients scheduled for bariatric surgery. Dexmeditomidine will be infused intraoperatively after induction of anesthesia. lung mechanics (dead space and compliance) as well as oxygenation (PF ratio) will be monitored intraoperatively and postoperatively

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: August 26, 2017
• Est. primary completion date: August 26, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Morbid obese (body mass index > 40) with documented restrictive lung disease scheduled to bariatric operation.

Exclusion Criteria:

• Heart failure

• ????Arrhythmia

• Heart block

• Severe liver or kidney impairment.

Related Conditions & MeSH terms

• Lung Diseases
• Restrictive Lung Disease

Intervention

Drug:
• Dexmedetomidine
Dexmedetomidine infusion was previously reported to improve oxygenation and lung dynamics in patients with obstructive lung diseases. In our study we are going to investigate its effect on oxygenation and lung dynamics in restrictive lung disease
• Normal saline
Normal saline

Locations

Country	Name	City	State
Egypt	Cairo University	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Oxygenation	assessed by P/F ratio	2 hours
Secondary	Lung mechanics	lung compliance and dead space	2 hours
Secondary	arterial blood pressure	arterial blood pressure measured in mmHg	2 hours
Secondary	plateau airway pressure	plateau airway pressure measured in cmH2o	2 hours
Secondary	heart rate	number of heart beats per minute	2 hours